Protalix BioTherapeutics (PLX) Receivables - Net (2016 - 2025)
Protalix BioTherapeutics (PLX) has 16 years of Receivables - Net data on record, last reported at $14.4 million in Q3 2025.
- For Q3 2025, Receivables - Net rose 557.18% year-over-year to $14.4 million; the TTM value through Sep 2025 reached $14.4 million, up 557.18%, while the annual FY2024 figure was $2.9 million, 44.82% down from the prior year.
- Receivables - Net reached $14.4 million in Q3 2025 per PLX's latest filing, up from $9.4 million in the prior quarter.
- Across five years, Receivables - Net topped out at $14.4 million in Q3 2025 and bottomed at $1.3 million in Q1 2023.
- Average Receivables - Net over 5 years is $5.5 million, with a median of $4.6 million recorded in 2021.
- Peak YoY movement for Receivables - Net: plummeted 77.93% in 2023, then surged 557.18% in 2025.
- A 5-year view of Receivables - Net shows it stood at $3.4 million in 2021, then soared by 33.24% to $4.6 million in 2022, then increased by 14.96% to $5.3 million in 2023, then tumbled by 44.82% to $2.9 million in 2024, then soared by 395.87% to $14.4 million in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Net were $14.4 million in Q3 2025, $9.4 million in Q2 2025, and $4.7 million in Q1 2025.